Boston Scientific Reports Third Quarter 2026 Financial Results

Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% year over year, with GAAP EPS of $0.40 and adjusted EPS of $0.73. MedSurg sales grew 0.6%, while Cardiovascular sales increased 1.9%. The company forecast full-year 2026 adjusted EPS of $3.16–$3.18 and reported sales growth of about 4.25%; for the fourth quarter, it expects adjusted EPS of $0.77–$0.79 and sales to decline 1%–3% year over year.